Sonal Shah

life sciences researcher @DeloitteHealth interested in the intersection of policy, business, and scientific innovation. frequent NYC art museum goer.

[Antonio Ciaccia @A_Ciaccia]

This is outstanding stuff from @gvanantwerp @Sonal_S_Shah @UsmanovaElsner and others at @DeloitteHealth on the future roles of pharmacists https://t.co/BJjYjNLzDu

[Drug Channels @DrugChannels]

From @DeloitteHealth: Useful #channel #strategy framework for #specialty #drugs, with helpful product archetype examples.

https://t.co/dWCHu3kvtF

Pharma channel strategy is simple, but not necessarily easy.

@gvanantwerp

[Sonal Shah @Sonal_S_Shah]

Explore how the #Biopharma industry can improve consumer trust levels with 5 elements of a successful communications strategy in the #HealthForward blog. https://t.co/LdN5SnoNsW

[Deloitte Life Sciences & Health Care @DeloitteHealth]

On April 8, Deloitte will convene some of the brightest minds in #healthcare and #publichealth to discuss how the pandemic can act as a catalyst to a reimagined future. Register for the event today!
https://t.co/9OiJ4C7rAJ

[David Betts @Dabetts_burgh]

I am really looking forward to this discussion on #COVID19 and #healthequity Join us!

[Sonal Shah @Sonal_S_Shah]

We’re in the earliest stages of an effort to vaccinate the world against #COVID19 and many questions around cost and value remain. Learn what we know and what we don’t in our #HealthForward blog. https://t.co/dOqBB0Duv9

[Sonal Shah @Sonal_S_Shah]

Pharmaceutical companies are proactively working to address inequities in health care by increasing diversity in clinical trials. @PhRMA's clinical trial diversity principles are a very important first step. https://t.co/IQmJ9cNxS3 via @statnews

[Sonal Shah @Sonal_S_Shah]

How can stakeholders come together to address the biggest challenges facing next-generation cell and gene therapies related to affordability and accessibility? Learn more in my latest piece on Deloitte’s Health Forward blog: Deloitte US https://t.co/2vKX0uPPKb via @DeloitteHealth

[Anjelika Deogirikar Grossman (she/her) @anjelikadeo]

Join on me Tuesday for this free event to discuss the impact of COVID on education - open to everyone! I’ll be speaking from my perspective as an educator alongside a high school student, physicians, and parents. https://t.co/Tpz0rusXMb cc: @SAforBiden @JoeMamas2020

[Sonal Shah @Sonal_S_Shah]

#COVID19 is disproportionately affecting Blacks, Latinos, and indigenous people, exposing the long-standing impacts of #racism in creating health care disparities. Racism is a public health crisis. https://t.co/je5Hxc3gJq

[Sonal Shah @Sonal_S_Shah]

Could COVID19 finally the catalyst that enables #pharmacists to operate at the top of their license? Great perspective from my colleague @gvanantwerp https://t.co/g5zAN1yY7p

[Matthew Herper @matthewherper]

Chaos! https://t.co/JeZ47Yhufk

[Sonal Shah @Sonal_S_Shah]

Data shows that a coordinated, collaborative approach to clinical trials would have taken us much further in understanding treatments for COVID19. What we do know, we've learned from a large scale pragmatic trial, the UK RECOVERY study
https://t.co/UmwJ4H5LbX via @statnews

[Sonal Shah @Sonal_S_Shah]

Pragmatic trials seem to be the best path forward to understand what treatments are working for COVID-19

[Scott Gottlieb, MD 🇺🇸 @ScottGottliebMD]

My @WSJ Op Ed. Rules for Clinical Trials in a Pandemic. A study out of Britain shows how to learn more, faster about promising Covid treatments. We'll be increasingly dependent on medical innovation as U.S. experiences persistently high Covid infection. https://t.co/cfeCaVxnU9

[Sonal Shah @Sonal_S_Shah]

New study shows some aspects of evidence based medicine are based on outdated and racially biased data

[Sonal Shah @Sonal_S_Shah]

RWE presents a tremendous opportunity to improve the declining returns on #pharma R&D. Companies that have already invested in more mature #RWE capabilities are already reaping the rewards. Read more in the latest installment of our RWE survey.

https://t.co/3djqHO1C68

[Sonal Shah @Sonal_S_Shah]

Our survey of clinical leaders shows that top concerns around restarting non-urgent procedures post lifting of #covid19 restrictions include a potential second outbreak, low patient demand, and lack of adequate supplies

https://t.co/3t93rupBgI

[Joe Ucuzoglu @jucuzoglu]

No words can describe the anger and hurt all of us are feeling. Silence is unacceptable. Deloitte is deeply committed to inclusion and stands against the legacy of systemic bias, racism and unequal treatment that continues to plague our communities. https://t.co/rcMbejqFqn

[David Shaywitz @DShaywitz]

Super interesting that Roche/Genentech new head of gRED (early R&D, mantra is “living 10y in the future”)= Aviv Regev of @broadinstitute . In case you needed more convincing that future of biopharma R&D involves computational biology and data science... https://t.co/jxORdjUarT

[Sonal Shah @Sonal_S_Shah]

Unprecedented levels of collaboration in biopharma for treatments and vaccines for #COVID19 could change the future of drug development. Check out my latest piece in @DeloitteHealth here: https://t.co/8ROiMWLML5 #covidresearch